Chương 24: CHAPTER TWENTY-FOUR: WASHINGTON IN THE LABORATORY

Amara Washington had been in Greyhold for three weeks when she presented her initial pharmaceutical assessment to Marcus and Okafor. She had been given the storage room adjacent to the clinic — a space that Briggs had evaluated and modified for her, improving the ventilation and adding a dedicated fire source for controlled heating, installing shelving at heights she specified with a specificity that suggested she had already designed the workflow she intended to execute in the space.

She had spent the three weeks doing what she did: assessing resources.

The assessment she presented was forty pages in her small, precise handwriting — the cramped technical script of someone who had spent years writing field reports in conditions where brevity and precision were both essential — and covered: every plant, mineral, and animal-derived substance available within reasonable collection range; their chemical properties as she understood them from her training and extrapolated from period herbal knowledge; and her preliminary analysis of what could be synthesized from available materials and at what confidence level.

She presented it standing at the clinic table with the composed authority of a professional who had done this kind of briefing before and had no anxiety about the audience.

"Tier one," she said.

"High confidence, near-term production. Basic antiseptic compounds — there are three different plant sources locally available that contain compounds with documented antimicrobial properties, and I can extract and concentrate them to effective strength within my current setup." She paused.

"This addresses wound cleaning. It won't prevent systemic infection in serious wounds, but it significantly reduces surface contamination and the most common secondary complications." Okafor was reading the relevant section of the report.

"The alcohol extraction for the elder compound — you're planning to build a still?"

"I need a still, yes. Briggs says he can build one in a week. Two, actually — one for the pharmaceutical operation, one he's going to give to you for general morale purposes." Washington almost smiled.

"He was very clear about that."

"He would be," Okafor said.

"What's tier two?"

"Pain management. More complex extraction, less confidence in concentration consistency, but the active compounds in two of the local plants have the right profile for mild-to-moderate pain relief. The challenge is dosing — I can get an effective compound but calibrating the dose for individual patients is going to require Okafor's clinical judgment on top of my chemistry."

"That's workable," Okafor said.

"We'll calibrate together." This story is posted elsewhere by the author. Help them out by reading the authentic version.

"Tier three is the problem," Washington said.

"Anti-infection treatment for serious systemic infection. The penicillin pathway is theoretically available — the right mold exists in the local environment, I've found traces of it in two different locations — but the isolation and concentration process requires equipment I don't have and some of the intermediate steps involve reagents I can't currently produce." She paused.

"The timeline for tier three is one to two years, minimum. If I can get specific equipment improvements from Briggs, possibly faster."

"A year or two years," Marcus said.

"It's the chemistry," Washington said.

"I can't make it go faster than the process allows. But tier one and two I can have operational within eight weeks." Eight weeks. That was summer. Marcus thought about the respiratory cases in February, about the family in the lower district, about Okafor's careful accounting of preventable deaths. Eight weeks to having something real for wound care and pain management. A year or two to having something that could address serious infection. Not fast enough for the people dying now.

Faster than anything that would have happened without this.

"What do you need?" he said. She gave him the list. It was specific and reasonable — equipment modifications from Briggs, specific plant materials from the surrounding territory, access to the clinic's existing herbal stores for the compounds she could work with directly, and a request that Marcus found both pragmatic and slightly unexpected: access to the network.

"The network?" he said.

"Whoever else is out there with scientific or medical training," she said.

"I don't know what I'm missing because I don't know what I don't know. If there's someone in the district with chemistry background or pharmacological knowledge, I want to know about it." She paused.

"The resources in this world are different from what I trained with. Someone else might have found a pathway I haven't considered."

"I'll make inquiries," Marcus said. He was thinking about the still-unconfirmed possibilities in Hatch's Ford and Millrun, and about the names on the roster that included a combat surgeon and two additional medical specialists he hadn't located yet.

"I'll find out who's available." After Washington left, Marcus and Okafor sat at the clinic table and Okafor said: "She's extraordinary."

"Yes," Marcus said.

"EOD to pharmaceutical chemistry is not an obvious translation," Okafor said.

"But the underlying skill — understanding complex chemical reactions, knowing what happens under what conditions, being precise about concentration and timing — transfers completely." She paused.

"She's going to save lives in ways I couldn't have imagined doing with what was available here."

"How does it feel?" Marcus said.

"Having someone who can do the chemistry side." Okafor was quiet for a moment.

"It feels like having backup," she said.

"After a year of knowing what needs to be done and not being able to do all of it — having someone who can do the part I couldn't do." She paused.

"It's the best thing that's happened since you found me." Marcus said nothing. The observation didn't require a response.